.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

In-person and virtual events just for HCPs

SpecialtySee All >

Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer

Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

I/O-Based Therapy in Non–Small Cell Lung Cancer

EP. 1: Nondriver Adenocarcinoma: Determining Therapy

July 16th 2020

EP. 2: ASCO 2020 Data Update: CheckMate 227

July 16th 2020

EP. 3: CheckMate-227 Regimen Safety Profile

July 16th 2020

EP. 4: Recent Combination Approval: CheckMate-9LA Regimen

July 16th 2020

EP. 5: CheckMate-9LA: Histology and Frontline Impact

July 16th 2020

EP. 6: Frontline PD-L1 Monotherapy: KEYNOTE-042 and IMpower110

July 16th 2020

EP. 7: PD-L1 Combination Therapy Clinical Trials

July 16th 2020

EP. 8: CheckMate 817 Overview

July 16th 2020

EP. 9: Squamous Cell Frontline Therapy: IMpower 131, KEYNOTE-407

July 16th 2020

EP. 10: NSCLC Management: Second-Line Options

July 16th 2020